Russell I J, Vipraio G A, Morgan W W, Bowden C L
Am J Med. 1986 Sep 29;81(3A):50-4. doi: 10.1016/0002-9343(86)90874-0.
Patients with the fibrositis syndrome experience moderately severe musculoskeletal discomfort, mood changes associated with nonrestorative sleep, and tenderness to palpation at specific body sites. There is no characteristic abnormal laboratory finding in these patients to help identify the population. A report by Moldofsky and Warsh (Pain 1978; 5: 65-71) of low serum levels of free tryptophan in patients with severe fibrositis syndrome is intriguing but remains unexplained. Those data plus the observation by Hudson et al (Am J Psychiatry 1985; 142: 441-446; Biol Psychiatry 1984; 19: 1489-1493) that patients with fibrositis syndrome exhibit an increased prevalence of anxiety and depression suggest a number of possible avenues for further study. They include potential alterations in the homeostasis of catecholamines, corticosteroids, serotonin, aromatic amino acids, platelet membrane receptor levels, and the activity of platelet membrane monoamine oxidase. Among these possibilities, evidence is now available that suggests an increased production of catecholamines in fibrositis syndrome.
纤维肌痛综合征患者会经历中度严重的肌肉骨骼不适、与非恢复性睡眠相关的情绪变化以及特定身体部位触诊压痛。这些患者没有特征性的异常实验室检查结果来帮助识别该人群。莫尔多夫斯基和沃什（《疼痛》1978年；5：65 - 71）关于严重纤维肌痛综合征患者血清游离色氨酸水平低的报告很有趣，但仍无法解释。这些数据加上哈德森等人（《美国精神病学杂志》1985年；142：441 - 446；《生物精神病学》1984年；19：1489 - 1493）的观察结果，即纤维肌痛综合征患者焦虑和抑郁的患病率增加，提示了一些可能的进一步研究途径。它们包括儿茶酚胺、皮质类固醇、血清素、芳香族氨基酸、血小板膜受体水平和血小板膜单胺氧化酶活性的内稳态的潜在改变。在这些可能性中，现在有证据表明纤维肌痛综合征中儿茶酚胺的产生增加。
